Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Groundbreaking Web Technology Shows Widely Varying Attitudes Regarding the Appropriate Use of Anticoagulants Like Coumadin and Other Blood Thinners

November 16, 2010

Wool.labs, a business intelligence company driven by social cognition technology, has published a revealing study through SmartBrief, showing confusion among patients and disagreement among physician specialties about the appropriate use of anticoagulants such as Coumadin. The study found that patients steadily increased their self-education efforts from 1999 through 2010 due to differing physician attitudes towards treatment and inconsistent information.

Wayne, Pa. (PRWEB) November 15, 2010

Wool.labs, a business intelligence company driven by social cognition technology, has published a revealing study through SmartBrief, showing confusion among patients and disagreement among physician specialties about the appropriate use of anticoagulants such as Coumadin (manufactured by Bristol-Meyers Squibb) or the generic form warfarin.

The study leveraged Wool.labs’ unique WebDig technology to track every conversation accessible on the internet to evaluate understanding and attitudes about anticoagulants ““ a treatment that has been available for over 60 years.

“The patterns in social media conversations suggest that patients believe they must educate themselves and each other – and even, at times, their physicians” stated Michele Bennett, Chief Operating Officer of Wool.labs. “We see that the self-education effort has increased from 1999 until today.”

The study further found that INR testing and awareness is low and seems to be a gap in patient self-education as well as drug interactions (beyond antiplaque treatment) and dosing. Life-long treatment is questioned in later years. Food and natural supplements are believed by some to be able to replace or reduce the need for life-long treatment.

Physicians do not always agree on treatment course and that may contribute to patients feeling that they need to be more in control of what happens to them both during and after treatment. Physician dissent remained present even through 2010.

Wool.labs created a way to measure audience sentiment online, in order to provide a more in depth analysis of how products like Coumadin are being regarded on the market. “We developed our Sentiment Index to provide a consistent, repeatable and trackable method to see how sentiment changes over time related to a particular topic” said Bennett. “Since WebDig is able to measure all of the conversations on the Internet, the only tool of its kind, we have an indicator that is comprehensive yet easy to use as part of other quantitative analyses. An industry expert develops reports from the data in the WebDig dashboard and we make both the dashboard and the report available to our clients.”

Scott Reese, CEO of Wool.labs sums up the significance of the report’s findings: “The results from this anticoagulation study, as well as many others we have done, are eye-opening in their clarity and predictive accuracy. While some “Ëœmonitor’ their brands or company, we see the opportunity to understand attitudes and address key business issues. User generated content in social media is an incredibly rich source of unstructured data and is full of insights. The key is to leverage technology that can make sense of it and bring those insights forward. That’s what we do.”

The Patient Social Intelligence Report is a series of retrospective and predictive analyses created by Wool.labs that digs into the hottest topics in the Health Care and Pharmaceutical industries across a variety of diseases and conditions to understand the sentiment, behavior and beliefs of patients and the impact on business of health care.

Wool.labs is a new breed of business intelligence software provider. Our proprietary technology solutions help enterprise clients understand and solve complex business challenges through Social Cognition. We dig deep into dialogue data to uncover core insights and emerging trends to inform strategy, change behavior and drive new business opportunities in a way that is unmatched in the industry.

Contact

For more information, visit http://woollabs.com/anticoagulation_pr.aspx

or contact Steve Chiles

888-966-5527 x777

schiles(at)woollabs(dot)com

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2010/11/prweb4782944.htm


Source: prweb